Dana-Farber Cancer Institute

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Dana-Farber Cancer Institute

https://www.dana-farber.org/

LYNKED IN Patient Conference 2024
Multiple Myeloma Patient Symposium
2023-2024 EMBRACE MBC Virtual Forum Series
ASCO® GU 2024
ASCO® 2023
COVID-19
Leukemia
Lymphoma
Myeloma
MDS and MPN
Breast
Lung
Gynecologic
Genitourinary
Gastrointestinal
Colorectal
Basic Science
Supportive and Palliative Care
CNS
Skin
Head and Neck
Business

Playback speed

10 seconds

ASCO® 2023 Insights: "Epcoritamab + R² Regimen and Responses in High-Risk FL Regardless of POD24 Status"

By Insights from 2023 ASCO® Annual Meeting FEATURING Reid Merryman

290 views

June 27, 2023

Comments 0

Hypothetical Patient Case: Hepatocellular Carcinoma and Consideratio…

Feat. J. Gutierrez, J. Strauss

Challenges to Navigate in Locally Advanced or Metastatic EGFR+ NSCLC

Feat. M. Socinski, D. Waterhouse

Lymphoma

New

ASH 2024 Insights: Acalabrutinib, Venetoclax, and Obinutuzumab in Pa…

2024 ASH Annual Meeting Insights Hub

A. Kim

SOHO 2023: Bispecific Antibodies or CAR T-Cells for Indolent B-NHL?

SOHO 2023 Eleventh Annual Meeting

C. Jacobson

123 views

Phase 1/2 EPCORE NHL-2 Trial: Investigating Epcoritamab for R/R Foll…

Oncology Data Advisor

R. Merryman

53 views

ASCO® 2023 Insights: "Epcoritamab + R² Regimen and Responses in High…

Insights from 2023 ASCO® Annual Meeting

R. Merryman

290 views

Beyond Hyperviscosity: 80 Years and Counting - Treatment of Waldenst…

Indy Hematology Review

S. Treon

34 views

ASH 2022 on Ibrutinib and Venetoclax in Previously Untreated Waldens…

ASH 2022 Conference Coverage

J. Castillo

64 views

Venetoclax in Previously Treated Waldenström Macroglobulinemia

Dana-Farber Cancer Institute

J. Castillo

18 views